Human Metapneumovirus in Adults
Human metapneumovirus (HMPV) is a relative newly described virus. It was first isolated in 2001 and currently appears to be one of the most significant and common human viral infections. Retrospective serologic studies demonstrated the presence of HMPV antibodies in humans more than 50 years earlier...
| Main Authors: | , , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
MDPI
2013
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3564111/ |
| id |
pubmed-3564111 |
|---|---|
| recordtype |
oai_dc |
| spelling |
pubmed-35641112013-02-11 Human Metapneumovirus in Adults Haas, Lenneke E. M. Thijsen, Steven F. T. van Elden, Leontine Heemstra, Karen A. Review Human metapneumovirus (HMPV) is a relative newly described virus. It was first isolated in 2001 and currently appears to be one of the most significant and common human viral infections. Retrospective serologic studies demonstrated the presence of HMPV antibodies in humans more than 50 years earlier. Although the virus was primarily known as causative agent of respiratory tract infections in children, HMPV is an important cause of respiratory infections in adults as well. Almost all children are infected by HMPV below the age of five; the repeated infections throughout life indicate transient immunity. HMPV infections usually are mild and self-limiting, but in the frail elderly and the immunocompromised patients, the clinical course can be complicated. Since culturing the virus is relatively difficult, diagnosis is mostly based on a nucleic acid amplification test, such as reverse transcriptase polymerase chain reaction. To date, no vaccine is available and treatment is supportive. However, ongoing research shows encouraging results. The aim of this paper is to review the current literature concerning HMPV infections in adults, and discuss recent development in treatment and vaccination. MDPI 2013-01-08 /pmc/articles/PMC3564111/ /pubmed/23299785 http://dx.doi.org/10.3390/v5010087 Text en © 2013 by the authors; licensee MDPI, Basel, Switzerland. http://creativecommons.org/licenses/by/3.0/ This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/). |
| repository_type |
Open Access Journal |
| institution_category |
Foreign Institution |
| institution |
US National Center for Biotechnology Information |
| building |
NCBI PubMed |
| collection |
Online Access |
| language |
English |
| format |
Online |
| author |
Haas, Lenneke E. M. Thijsen, Steven F. T. van Elden, Leontine Heemstra, Karen A. |
| spellingShingle |
Haas, Lenneke E. M. Thijsen, Steven F. T. van Elden, Leontine Heemstra, Karen A. Human Metapneumovirus in Adults |
| author_facet |
Haas, Lenneke E. M. Thijsen, Steven F. T. van Elden, Leontine Heemstra, Karen A. |
| author_sort |
Haas, Lenneke E. M. |
| title |
Human Metapneumovirus in Adults |
| title_short |
Human Metapneumovirus in Adults |
| title_full |
Human Metapneumovirus in Adults |
| title_fullStr |
Human Metapneumovirus in Adults |
| title_full_unstemmed |
Human Metapneumovirus in Adults |
| title_sort |
human metapneumovirus in adults |
| description |
Human metapneumovirus (HMPV) is a relative newly described virus. It was first isolated in 2001 and currently appears to be one of the most significant and common human viral infections. Retrospective serologic studies demonstrated the presence of HMPV antibodies in humans more than 50 years earlier. Although the virus was primarily known as causative agent of respiratory tract infections in children, HMPV is an important cause of respiratory infections in adults as well. Almost all children are infected by HMPV below the age of five; the repeated infections throughout life indicate transient immunity. HMPV infections usually are mild and self-limiting, but in the frail elderly and the immunocompromised patients, the clinical course can be complicated. Since culturing the virus is relatively difficult, diagnosis is mostly based on a nucleic acid amplification test, such as reverse transcriptase polymerase chain reaction. To date, no vaccine is available and treatment is supportive. However, ongoing research shows encouraging results. The aim of this paper is to review the current literature concerning HMPV infections in adults, and discuss recent development in treatment and vaccination. |
| publisher |
MDPI |
| publishDate |
2013 |
| url |
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3564111/ |
| _version_ |
1611952518487605248 |